Julia Auer

Phase I study of AG-120, an IDH1 mutant enzyme inhibitor: Results from the cholangiocarcinoma dose escalation and expansion cohorts.

Maeve A. Lowery, Ghassan K. Abou‐Alfa, Howard A. Burris et al. · Journal of Clinical Oncology · 2017 · 93 citations

Medicine, Oncology, Pharmacology +14

Smart textiles in wound care: functionalization of cotton/PET blends with antimicrobial nanocapsules

Felice Quartinello, Claudia Tallian, Julia Auer et al. · Journal of Materials Chemistry B · 2019 · 34 citations

Arts, Materials Engineering, Materials Science +17

ACTR-46. AG120, A FIRST-IN-CLASS MUTANT IDH1 INHIBITOR IN PATIENTS WITH RECURRENT OR PROGRESSIVE IDH1 MUTANT GLIOMA: RESULTS FROM THE PHASE 1 GLIOMA EXPANSION COHORTS

Ingo K. Mellinghoff, Mehdi Touat, Elizabeth A. Maher et al. · Neuro-Oncology · 2016 · 20 citations · Full text

Medicine, Oncology, Pharmacology +17

<i>Anaplasmataceae-</i>Specific PCR for Diagnosis and Therapeutic Guidance for Symptomatic Neoehrlichiosis in Immunocompetent Host

Michael Schwameis, Julia Auer, Dieter Mitteregger et al. · Emerging infectious diseases · 2016 · 12 citations · Full text

Veterinary Medicine, Infectious Diseases, Microbiology +10

511 Initial results of a phase 1 study of intratumoral ONCR-177, an oncolytic herpes-simplex virus-1 expressing five immunomodulatory transgenes, in subjects with advanced injectable tumors

Jong Chul Park, Hatem Soliman, Gerald S. Falchook et al. · Regular and Young Investigator Award Abstracts · 2021 · 10 citations · Full text

Medicine, Immunology, Oncology +17